

## Product datasheet for **KN400661**

### HLAA (HLA-A) Human Gene Knockout Kit (CRISPR)

#### Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	HLAA
Locus ID:	3105
Components:	<p><b>KN400661G1</b>, HLAa gRNA vector 1 in pCas-Guide CRISPR vector (GE100002), Target Sequence: ATTTCTTCACATCCGTGTCC</p> <p><b>KN400661G2</b>, HLAa gRNA vector 2 in pCas-Guide CRISPR vector (GE100002), Target Sequence: CGTAGCCCACGGCGATGAAG</p> <p><b>KN400661D</b>, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP: The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.</p>

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGGG GAGGGTTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGTAAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCGC CTTTTCCCG AGGGTGGGGG AGAACCCTAT
ATAAGTGAC TAGTCGCCGT GAACGTTCTT TTTCCGAACG GGTTCGCCGC CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTCCACCTG
GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTCGCCTCG TGCTTGAGTT GAGGCCTGGC CTGGGGCTG GGGCCGCGC GTGCGAATCT
GGTGGCACCT TCGCGCCTGT CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTTT GATGACCTGC
TGCGACGCTT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCGAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCCGCCCT GGGCGGCAAG GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGCTTCCCG GCCCTGCTGC AGGGAGCTCA AAATGGAGGA CGCGGCCTC GGGAGAGCGG GCGGGTGAGT
CACCCACACA AAGGAAAAGG GCCTTCCGT CTCAGCCGT CGTTTCATGT GACTCCACGG AGTACCGGGC
GCCGTCCAG CACCTCGATT AGTTCTCGAG CTTTTGAGT ACGTCTGCTT TAGGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAC TTGATGTAAT
TCTCCTTGA ATTTGCCCTT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCCTACC TGCTGAGCCA
CGTGATGGG TACGGCTTCT ACCACTTCGG CACCTACCC AGCGGTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCGC ATCGAGAAGT ACGAGGACGG CGGCGTGCT CACGTGAGCT
TCAGTACCG CTACGAGGCC GGCCGCGTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCCGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGGCGAT

```



```

AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTACTIONACAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCCA TGTTCCGCTT
CCGCCGCGTG GAGGAGGATC ACAGCAACAC CGAGCTGGGC ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTACTIONCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC CACGGTGGC CTCGCCACCC GCGACGACGT
CCCCAGGGCC GTACGCACCC TCGCCGCCG GTTCGCCGAC TACCCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC GACATCGGCA
AGGTGTGGGT CGCGGACGAC GCGGCCGCGG TGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGCCCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGA CCGGCCAAG GAGCCCGCT GGTTCCTGGC CACCGTCGGC GTCTCGCCG
ACCACCAGGG CAAGGTCTG GGCAGCGCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTC CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGAA GCCCGGTGCC TGAAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```


**Disclaimer:**

These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

**RefSeq:**

[NM\\_001242758](#), [NM\\_002116](#)

**UniProt ID:**

[P01892](#)

**Synonyms:**

HLAA

**Summary:**

HLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen so that they can be recognized by cytotoxic T cells. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. More than 6000 HLA-A alleles have been described. The HLA system plays an important role in the occurrence and outcome of infectious diseases, including those caused by the malaria parasite, the human immunodeficiency virus (HIV), and the severe acute respiratory syndrome coronavirus (SARS-CoV). The structural spike and the nucleocapsid proteins of the novel coronavirus SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), are reported to contain multiple Class I epitopes with predicted HLA restrictions. Individual HLA genetic variation may help explain different immune responses to a virus across a population.[provided by RefSeq, Aug 2020]

**Product images:**
